Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.36 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.36 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.36 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.34 |
| ▸ | GABRP | O00591 | 2/20 | 0.32 |
| ▸ | GABRD | O14764 | 2/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.32 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6155785 | 0.88 | CAMK2A (0.40) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL10478922 | 0.84 | CAMK2A (0.43) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL6694390 | 0.82 | BLM (0.35) | BLMCACNA2D1CACNB3CACNA1CPGR | |
| SCHEMBL18704287 | 0.80 | BHMT (0.44) | BLMACE2CAMK2AGPR84BHMT | |
| SCHEMBL28674069 | 0.80 | GPR84 (0.42) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL426173 | 0.80 | BHMT (0.44) | BLMACE2CAMK2AGPR84BHMT | |
| SCHEMBL9460828 | 0.80 | BHMT (0.44) | BLMACE2CAMK2AGPR84BHMT | |
| SCHEMBL692357 | 0.79 | SLC22A6 (0.43) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL28834415 | 0.79 | GPR84 (0.47) | LMNAGPR84FFAR1FFAR4 | |
| SCHEMBL3930995 | 0.79 | GPR84 (0.47) | ADRA1ALMNAGPR84FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2295409-B1 | FLUORO SUBSTITUTED CYCLOALKANOINDOLES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | MERCK CANADA INC (CA) | 2014-07-02 | — | — | EP | disclosed |
| EP-2116244-B1 | Method of treating atherosclerosis, dyslipidemias and related conditions | SCHERING CORP (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-2045241-B1 | Fluoro substituted cycloalkanoindoles and their use as prostaglandin D2 receptor antagonists | MERCK CANADA INC (CA) | 2012-07-04 | — | — | EP | disclosed |
| US-20120115921-A1 | FLUORO SUBSTITUTED CYCLOALKANOINDOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20110118292-A1 | METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS | CHENG KANG | 2011-05-19 | — | — | US | disclosed |
| EP-2295409-A1 | Fluoro substituted cycloalkanoindoles and their use as prostaglandin D2 receptor antagonists | Merck Frosst Canada Limited (CA) | 2011-03-16 | — | — | EP | disclosed |
| EP-2286816-A1 | Method of treating atherosclerosis, dyslipidemias and related conditions | MERCK SHARP & DOHME (I.A.) CORP. (US) | 2011-02-23 | — | — | EP | disclosed |
| US-20100081696-A1 | FLUORO SUBSTITUTED CYCLOALKANOINDOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | BERTHELETTE CARL | 2010-04-01 | — | — | US | disclosed |
| US-20100076002-A1 | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions and Pharmaceutical Compositions | CHENG KANG | 2010-03-25 | — | — | US | disclosed |
| US-7618994-B2 | Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment | MERCK FROSST CANADA LTD. (CA) | 2009-11-17 | — | — | US | disclosed |
| WO-2006052555-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| US-20060069148-A1 | Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment | BERTHELETTE CARL | 2006-03-30 | — | — | US | disclosed |
| WO-2006026273-A2 | METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS | MERCK & CO., INC. (US) | 2006-03-09 | — | — | WO | disclosed |
| EP-1624871-A1 | METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS AND PHARMACEUTICAL COMPOSITIONS | Merck & Co., Inc. (a New Jersey corp.) (US) | 2006-02-15 | — | — | EP | disclosed |
| US-20050124680-A1 | Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment | MERCK CANADA INC. (CA) | 2005-06-09 | — | — | US | disclosed |
| WO-2004103370-A1 | METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS AND PHARMACEUTICAL COMPOSITIONS | MERCK & CO., INC. (US) | 2004-12-02 | — | — | WO | disclosed |
| US-20040229844-A1 | Method of treating atherosclerosis, dyslipidemias and related conditions | CHENG KANG (US) | 2004-11-18 | — | — | US | disclosed |
| EP-1470107-A2 | FLUORO SUBSTITUTED CYCLOALKANOINDOLES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | Merck Frosst Canada & Co. (CA) | 2004-10-27 | — | — | EP | disclosed |
| US-20030158246-A1 | For the treatment of prostaglandin mediated diseases, such as allergic asthma or rhinitis. | MERCK FROSST CANADA & CO. (CA) | 2003-08-21 | — | — | US | disclosed |
| WO-2003062200-A2 | FLUORO SUBSTITUTED CYCLOALKANOINDOLES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA & CO. (CA) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069148-A1 | Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment | PTGER1, PTGER3, PTGER2 | BLM 1445/4885CACNA2D1 4798/4885CACNB3 2464/4885 |
| US-20120115921-A1 | FLUORO SUBSTITUTED CYCLOALKANOINDOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | PTGER1, PTGER3, PTGER2 | BLM 1445/4885CACNA2D1 4798/4885CACNB3 2464/4885 |
| US-20030158246-A1 | For the treatment of prostaglandin mediated diseases, such as allergic asthma or rhinitis. | PTGES, PTGIR, PTGER1 | BLM 3320/4885CACNA2D1 4858/4885CACNB3 3915/4885 |
| US-20050124680-A1 | Fluoro substituted cycloalkanoindoles, compositions containing such compounds and methods of treatment | PTGER1, PTGER3, PTGER2 | BLM 1445/4885CACNA2D1 4798/4885CACNB3 2464/4885 |
| US-20100076002-A1 | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions and Pharmaceutical Compositions | LDLR, LPAR5, FFAR1 | BLM 4086/4885CACNA2D1 1530/4885CACNB3 689/4885 |
| US-20100081696-A1 | FLUORO SUBSTITUTED CYCLOALKANOINDOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | PTGER1, PTGER3, PTGER2 | BLM 1445/4885CACNA2D1 4798/4885CACNB3 2464/4885 |
| US-20110118292-A1 | METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS | LDLR, HCAR1, FFAR1 | BLM 3947/4885CACNA2D1 1736/4885CACNB3 584/4885 |
| US-20040229844-A1 | Method of treating atherosclerosis, dyslipidemias and related conditions | LDLR, HCAR1, FFAR1 | BLM 3947/4885CACNA2D1 1736/4885CACNB3 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.